Tenderwize
Zurück zur Suche

Open-house rebate contracts for methoxy-polyethylene glycol-epoetin beta

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Methoxy-Polyethylenglycol-Epoetin beta, ATC B03XA03

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Paper submissions must be received in original form and in duplicate, with a scan sent in advance; electronic submissio...

Only pharmaceutical companies are eligible, and products must be approved and marketable in Germany. Products not liste...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate contracts for pharmaceutical products containing methoxy-polyethylene glycol-epoetin beta (ATC B03XA03).
  • Contract term: 01.02.2026 to 31.01.2028, with monthly entry possible during the term.
Vollständige Zusammenfassung anzeigen

This is a German open-house supply arrangement for non-exclusive pharmaceutical rebate contracts for methoxy-polyethylene glycol-epoetin beta (ATC B03XA03) with AOK Rheinland-Pfalz/Saarland. The notice states that any interested pharmaceutical company may join on equal terms, but no individual negotiations take place. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the term, subject to the stated submission rules. Electronic submission is not allowed; documents must be submitted in paper form or by email only if signed with a qualified electronic signature. The notice also states that the procedure is not a public procurement contract in the sense of Directive 2014/24/EU, although it is published in TED for transparency.

Risiken

Paper submissions must be received in original form and in duplicate, with a scan sent in advance; electronic submissio...

Only pharmaceutical companies are eligible, and products must be approved and marketable in Germany. Products not liste...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only approved and marketable medicines in Germany may be supplied under the contract.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate contracts for methoxy-polyethylene glycol-epoetin beta

Single lot covering non-exclusive open-house rebate contracts for medicines containing methoxy-polyethylene glycol-epoetin beta (ATC B03XA03). The scope is limited to the stated active substance; medicines listed as pediatric medicines under the BfArM list are excluded. Contract terms are uniform for all participants and no individual negotiation is foreseen. Lot information comes from structured data and notice text.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
817612-2025

Dokumente (1)

Ähnliche Ausschreibungen